CoChat

A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials

Open access
Wu, Xiaozheng, Li, Wen, Luo, Zhenliang, Chen, Yunzhi · 2024 · BMC Pulmonary Medicine

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Abstract

Objective: Randomized controlled trials(RCTs) of multiple drugs for Idiopathic pulmonary fibrosis(IPF) have been reported and achieved a certain degree of efficacy, however, the difference in safety and efficacy of them for IPF is not yet well understood. The aim of this network meta-analysis is to assess their safety and efficacy in the treatment of IPF and differences in this safety and efficacy comprehensively. Methods: The PubMed, EMbase, CENTRAL and MEDLINE were retrieved to find out the RCTs of drugs in the treatment of IPF. The retrieval date is from construction to November 10, 2022. Stata 14.0 and RevMan 5.3 was used for statistical analysis. Registration number: CRD42023385689. Results: Twenty-four studies with a total of 6208 patients were finally included, including RCTs of 13 drugs. The results of safety showed that there' s no difference in the incidence of SAEs of 13 drugs treated with IPF compared to placebo (P>0.05), and it’s also found that Warfarin had a higher all-cause mortality for IPF than placebo (OR = 5.63, 95% CI [1.54 to 20.55]). SUCRA' s scatterplot showed that Pirfenidone, Nintedanib, Sildenafil and Imatinib were lower than placebo, and Warfarin, Ambrisentan and N-acetylcysteine were higher than placebo. The results of effectiveness showed that Nintedanib (MD = -0.08, 95% CI [-0.12 to -0.04]) improved FVC (L)absolute change from baseline in patients better than placebo, and Nintedanib (OR=1.81, 95% CI [1.23 to 2.66]), Pirfenidone (OR=1.85, 95%CI [1.26 to 2.71]) and Pamrevlumab (OR=4.11, 95% CI [1.25 to 13.58]) improved the proportion of patients with a decline in FVC ≥10% predicted better than placebo. SUCRA' s scatterplot showed that Pamrevlumab, Pirfenidone and Nintedanib were lower than placebo, and Warfarin and Ambrisentan were higher than placebo. Conclusion: Compared with other drugs, Nintedanib and Pirfenidone can significantly slow the decline of lung function in patients with IPF, and the safety is higher. Therefore, they can be further promoted in clinical practice. Warfarin and Ambrisentan shouldn’t be used clinically for IPF as the safety and efficacy of them are poor compared to other drugs and placebo. Pamrevlumab may become important drugs for the treatment of IPF in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12890-024-02861-w

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA literature screening flow chart
Fig. 1 PRISMA literature screening flow chartCC BY · PubMed Central
Fig. 2 Bias risk percentage
Fig. 2 Bias risk percentageCC BY · PubMed Central
Fig. 3 Bias risk summary chart
Fig. 3 Bias risk summary chartCC BY · PubMed Central
Fig. 4 Network evidence map of SAEs. A total of 19 studies reported SAEs in the treatment of IPF with 13 drugs: 1 of Ambrisentan, 2 of Bosentan, 1 of GLPG1690, 1 of Imatinib, 1 of Macitentan, 1 of N-acetylcysteine, 5 of Nintedanib, 1 of Pamrevlumab, 2 of Pirfenidone, 1 of PRM-151, 1 of Sildenafil, 1 of Simtuzumab, 1 of Warfarin
Fig. 4 Network evidence map of SAEs. A total of 19 studies reported SAEs in the treatment of IPF with 13 drugs: 1 of Ambrisentan, 2 of Bosentan, 1 of GLPG1690, 1 of Imatinib, 1 of Macitentan, 1 of N-acetylcysteine, 5 of Nintedanib, 1 of Pamrevlumab, 2 of Pirfenidone, 1 of PRM-151, 1 of Sildenafil, 1 of Simtuzumab, 1 of WarfarinCC BY · PubMed Central
Fig. 5 Network evidence map of all-cause mortality. A total of 16 studies reported the all-cause mortality of IPF treated with 11 drugs: 1 of Ambrisentan, 2 of Bosentan,1 of Imatinib, 1 of Macitentan, 1 of N-acetylcysteine, 3 of Nintedanib, 1 of Pamrevlumab, 3 of Pirfenidone, 1 of Sildenafil, 1 of Simtuzumab, 1 of Warfarin
Fig. 5 Network evidence map of all-cause mortality. A total of 16 studies reported the all-cause mortality of IPF treated with 11 drugs: 1 of Ambrisentan, 2 of Bosentan,1 of Imatinib, 1 of Macitentan, 1 of N-acetylcysteine, 3 of Nintedanib, 1 of Pamrevlumab, 3 of Pirfenidone, 1 of Sildenafil, 1 of Simtuzumab, 1 of WarfarinCC BY · PubMed Central
Fig. 6 The scatterplot combining the results of the incidence of SAEs and all-cause mortality (SUCRA values). The horizontal coordinate represents SUCRA values for all-cause mortality and the vertical coordinate represents SUCRA values for SAEs.If drugs are positioned further to the upper right of the graph, it means that the higher their SUCRA values, the higher their risk; if drugs are positioned further to the lower left of the graph, it means that the lower their SUCRA values are lower, the lower the risk
Fig. 6 The scatterplot combining the results of the incidence of SAEs and all-cause mortality (SUCRA values). The horizontal coordinate represents SUCRA values for all-cause mortality and the vertical coordinate represents SUCRA values for SAEs.If drugs are positioned further to the upper right of the graph, it means that the higher their SUCRA values, the higher their risk; if drugs are positioned further to the lower left of the graph, it means that the lower their SUCRA values are lower, the lower the riskCC BY · PubMed Central
Fig. 7 Network evidence map of FVC (L) absolute change from baseline. A total of 11 studies reported the FVC (% predicted) absolute change from baseline in patients with IPF treated with 9 drugs:1 of Bosentan, 1 of GLPG1690, 1 of Imatinib, 1 of Macitentan, 1 of N-acetylcysteine, 3 of Nintedanib, 1 of Pamrevlumab, 1 of PRM-151, 1 of Warfarin
Fig. 7 Network evidence map of FVC (L) absolute change from baseline. A total of 11 studies reported the FVC (% predicted) absolute change from baseline in patients with IPF treated with 9 drugs:1 of Bosentan, 1 of GLPG1690, 1 of Imatinib, 1 of Macitentan, 1 of N-acetylcysteine, 3 of Nintedanib, 1 of Pamrevlumab, 1 of PRM-151, 1 of WarfarinCC BY · PubMed Central
Fig. 8 Network evidence map of FVC (% predicted)absolute change from baseline. A total of 9 studies reported the FVC (% predicted) absolute change from baseline in patients with IPF treated with 7 drugs: 1 of Ambrisentan, 1 of Nintedanib, 1 of Pamrevlumab, 2 of Pirfenidone, 1 of PRM-151, 2 of Sildenafil, 1 of Warfarin
Fig. 8 Network evidence map of FVC (% predicted)absolute change from baseline. A total of 9 studies reported the FVC (% predicted) absolute change from baseline in patients with IPF treated with 7 drugs: 1 of Ambrisentan, 1 of Nintedanib, 1 of Pamrevlumab, 2 of Pirfenidone, 1 of PRM-151, 2 of Sildenafil, 1 of WarfarinCC BY · PubMed Central
Fig. 9 Network evidence map of the proportion of patients with decline in FVC≥10% predicted. A total of 10 studies reported the effect of the proportion of patients with decline in FVC≥ 10% predicted of 5 drugs: 1 of Ambrisentan, 4 of Nintedanib, 1 of Pamrevlumab, 3 of Pirfenidone, 1 of Warfarin
Fig. 9 Network evidence map of the proportion of patients with decline in FVC≥10% predicted. A total of 10 studies reported the effect of the proportion of patients with decline in FVC≥ 10% predicted of 5 drugs: 1 of Ambrisentan, 4 of Nintedanib, 1 of Pamrevlumab, 3 of Pirfenidone, 1 of WarfarinCC BY · PubMed Central
Fig. 10 The scatterplot combining the results of FVC (% predicted)absolute change from baseline and the proportion of patients with decline in FVC≥10% predicted(SUCRA values). The horizontal coordinate represents SUCRA values for FVC (% predicted) absolute change from baseline and the vertical coordinate represents SUCRA values for the proportion of patients with decline in FVC ≥10% predicted. If drugs are positioned further to the upper right of the graph, it means that the higher their SUCRA values, the higher their risk; if drugs are positioned further to the lower left of the graph, it means that the lower their SUCRA values are lower, the lower the risk
Fig. 10 The scatterplot combining the results of FVC (% predicted)absolute change from baseline and the proportion of patients with decline in FVC≥10% predicted(SUCRA values). The horizontal coordinate represents SUCRA values for FVC (% predicted) absolute change from baseline and the vertical coordinate represents SUCRA values for the proportion of patients with decline in FVC ≥10% predicted. If drugs are positioned further to the upper right of the graph, it means that the higher their SUCRA values, the higher their risk; if drugs are positioned further to the lower left of the graph, it means that the lower their SUCRA values are lower, the lower the riskCC BY · PubMed Central
Fig. 11 The results of inverted funnel plots. a SAEs. b All-cause mortality. c FVC (L) absolute change from baseline. d FVC (% predicted)absolute change from baseline. e The proportion of patients with decline in FVC≥10% predicted. (PLA:Placebo; NIN:Nintedanib; PIR:Pirfenidone; SIL:Sildenafil; AMB:Ambrisentan; PAM:Pamrevlumab; BOS:Bosentan; MAC:Macitentan; IMA:Imatinib; GLPG:GLPG1690; SIM:Simtuzumab; WAR:Warfarin;PRM: PRM151;NAC:N-acetylcysteine.)
Fig. 11 The results of inverted funnel plots. a SAEs. b All-cause mortality. c FVC (L) absolute change from baseline. d FVC (% predicted)absolute change from baseline. e The proportion of patients with decline in FVC≥10% predicted. (PLA:Placebo; NIN:Nintedanib; PIR:Pirfenidone; SIL:Sildenafil; AMB:Ambrisentan; PAM:Pamrevlumab; BOS:Bosentan; MAC:Macitentan; IMA:Imatinib; GLPG:GLPG1690; SIM:Simtuzumab; WAR:Warfarin;PRM: PRM151;NAC:N-acetylcysteine.)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 92 references

Research works printed but not linked: 3

  1. van der Aar EM, Fagard L, Desrivot J, et al. Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;193:A2701.
  2. van der Aar EM, Heckmann B, Blanque R, et al. Pharmacological profile and efficacy of GLPG1690, a novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;193:A4532.
  3. Coornaert B, Duys I, Van Der Schueren J, van der Aar E, Heckmann B. Autotaxin inhibitor GLPG1690 affects TGFβ-induced production of the pro-fibrotic mediators CTGF, IL-6 and ET-1 in fibroblasts. Am J Respir Crit Care Med. 2017;195:A2404.

Cited by

See all 9

Metadata

Authors
Wu, X., Li, W., Luo, Z., & Chen, Y.
Corresponding author
Chen, Yunzhi
Venue
BMC Pulmonary Medicine
Published
2024-01-27
Volume
24
Issue
1
Pages
58-58
ISSN
1471-2466 (ISSN-L)
OpenAlex
W4391276765
Cited by
9
References
91
Citations by year
2026: 3 · 2025: 5 · 2024: 1
FWCI
2.60
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Pulmonary Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Guizhou Provincial Basic Research Progra (Qiankehe Foundation-ZK[2023]General 411)
  • Academic New Seedling Project of Guizhou University of Traditional Chinese Medicine (Guike Cooperative Academic New Seedling [2023]-22)
  • Innovation and Entrepreneurship Training Program for College Students of Guizhou University of Traditional Chinese Medicine, China (Gui Zhong Yi Da Chuang He Zi (2022) No. 90)
  • Project of Education Department of Guizhou Province, China (Guizhou Education Technology 2022-023)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
idiopathic pulmonary fibrosis, antifibrotic agents, drug safety, drug efficacy, nintedanib, pirfenidone, ambrisentan, sildenafil, warfarin, N-acetylcysteine, imatinib, forced vital capacity decline, all-cause mortality, serious adverse events, comparative effectiveness, surface under the cumulative ranking curve
MeSH terms
Humans, Phenylpropionates, Pyridazines, Pyridones, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials. https://app.cochat.ai/papers/10.1186/s12890-024-02861-w
The paper
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024). A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-024-02861-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.